Rivaroxaban: Expanded Role in Cardiovascular Disease Management-A Literature Review

Area of Science:

• Pharmacology and Therapeutics
• Cardiovascular Medicine
• Hematology

Background:

• Direct oral anticoagulants (DOACs) are established for stroke prevention in atrial fibrillation, venous thromboembolism treatment, and post-surgical prophylaxis.
• The therapeutic landscape for DOACs has expanded significantly over the past decade.
• Rivaroxaban, a direct factor Xa inhibitor, is a prominent DOAC with a growing range of evidence-based applications.

Purpose of the Study:

• To review the expanded, evidence-based indications for rivaroxaban.
• To provide an overview of rivaroxaban's use beyond its initial approvals.
• To synthesize current knowledge on rivaroxaban for various cardiovascular and medical conditions.

Main Methods:

• Literature review of clinical studies and guidelines.
• Analysis of evidence supporting expanded indications for rivaroxaban.
• Focus on factor Xa inhibitors, specifically rivaroxaban.

Main Results:

• Rivaroxaban is increasingly utilized for coronary artery disease and peripheral artery disease.
• Evidence supports rivaroxaban's role in heart failure management.
• Rivaroxaban shows utility in malignancy-related thrombosis and prophylaxis in acute medical illness.

Conclusions:

• Rivaroxaban's indications have expanded beyond traditional uses based on robust evidence.
• The factor Xa inhibitor offers therapeutic benefits across a spectrum of cardiovascular and thromboembolic conditions.
• Continued research and clinical application are refining the role of rivaroxaban in modern medicine.